Cannabis Use Linked to Shorter Hospital Stays and Lower Costs for IBD Patients After Legalization
After recreational cannabis legalization in Colorado and Washington, reported cannabis use among hospitalized IBD patients tripled, and cannabis users had shorter hospital stays and lower charges than non-users.
Quick Facts
What This Study Found
Reported cannabis use among IBD inpatients increased from 1.2% to 4.2% after legalization (p<0.05). In 2015, cannabis-using IBD patients had shorter hospital stays and $8,418 less in hospital charges (p=0.024) compared to non-users.
Key Numbers
Cannabis use: 1.2% (2011) vs 4.2% (2015, post-legalization). In 2015: shorter hospital stays (p=0.038) and $8,418 lower charges (p=0.024) for cannabis users. Analysis adjusted for demographic data.
How They Did This
Retrospective analysis comparing hospitalized IBD patients in Colorado and Washington before (2011) and after (2015) recreational cannabis legalization. Used chi-square and t-tests for comparisons, with multivariable regression adjusting for demographics.
Why This Research Matters
IBD patients frequently use cannabis for symptom management, and there is preclinical evidence for anti-inflammatory effects of cannabinoids in the gut. This study provides preliminary real-world data suggesting cannabis use does not worsen and may improve inpatient outcomes.
The Bigger Picture
This is one of the few studies linking cannabis legalization to specific disease outcomes beyond general population health metrics. The improved inpatient outcomes in cannabis-using IBD patients are intriguing given the known anti-inflammatory properties of cannabinoids.
What This Study Doesn't Tell Us
Retrospective design with potential confounders. Cannabis use was likely underreported, especially pre-legalization. The "cannabis use" category does not capture dose, frequency, or product type. Lower charges might reflect less severe disease in cannabis users rather than a treatment effect.
Questions This Raises
- ?Does cannabis genuinely reduce IBD inflammation, or are cannabis-using IBD patients simply less severely ill?
- ?Would a prospective study of cannabis use in IBD patients confirm shorter hospital stays?
- ?Which cannabinoid components might benefit IBD most?
Trust & Context
- Key Stat:
- $8,418 lower hospital charges for cannabis-using IBD inpatients
- Evidence Grade:
- Preliminary: retrospective analysis with limited ability to control for confounders and likely underreporting of cannabis use.
- Study Age:
- Published in 2022, comparing 2011 vs 2015 data.
- Original Title:
- Impact of Cannabis Use on Inpatient Inflammatory Bowel Disease Outcomes in 2 States Legalizing Recreational Cannabis.
- Published In:
- Crohn's & colitis 360, 4(2), otac015 (2022)
- Authors:
- Pusateri, Antoinette, Anaizi, Ahmad, Nemer, Laura, Hinton, Alice, Lara, Luis, Afzali, Anita
- Database ID:
- RTHC-04154
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Frequently Asked Questions
Does cannabis help with inflammatory bowel disease?
This study found cannabis-using IBD patients had shorter hospital stays and lower charges, but it cannot determine whether cannabis caused the improvement. Cannabis users might have had less severe disease to begin with.
Did legalization increase cannabis use among IBD patients?
Yes. Reported cannabis use among hospitalized IBD patients rose from 1.2% to 4.2% after recreational legalization, though actual use was likely higher given underreporting in both periods.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04154APA
Pusateri, Antoinette; Anaizi, Ahmad; Nemer, Laura; Hinton, Alice; Lara, Luis; Afzali, Anita. (2022). Impact of Cannabis Use on Inpatient Inflammatory Bowel Disease Outcomes in 2 States Legalizing Recreational Cannabis.. Crohn's & colitis 360, 4(2), otac015. https://doi.org/10.1093/crocol/otac015
MLA
Pusateri, Antoinette, et al. "Impact of Cannabis Use on Inpatient Inflammatory Bowel Disease Outcomes in 2 States Legalizing Recreational Cannabis.." Crohn's & colitis 360, 2022. https://doi.org/10.1093/crocol/otac015
RethinkTHC
RethinkTHC Research Database. "Impact of Cannabis Use on Inpatient Inflammatory Bowel Disea..." RTHC-04154. Retrieved from https://rethinkthc.com/research/pusateri-2022-impact-of-cannabis-use
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.